Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [IR] Samsung Electronics (005930) – Q2 2024 Earnings Presentation / 2024-07-31 IR Room
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Order Recovery · Plant Ramp-up · Earnings Growth / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Ultra-Low Inventory · Supply Shortage · Earnings Rebound / 2026-07-30 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | 4Q Earnings Recovery · New Plant Ramp-up · Peptide Expansion / 2026-07-24 Research

[Research] LIG D&A (079550) – SK Securities | Modern Warfare Leader · Limited Global CapEx · Multiple Re-rating / 2026-04-07

Posted on April 7, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : SK Securities

Analyst : Shane Han, RA Seoyoung Ko

Investment Rating : BUY (Initiate)

Target Price : KRW 1,150,000 (Initiate)

Core Momentum : Surging demand for interceptor missiles amid tight global capacity post-Iran war, with multi-year growth secured across Middle Eastern mass-production ramps and leadership across ISR, C4I, and PGM

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Initiate), Target Price KRW 1,150,000 (Initiate), Current Price KRW 810,000 (As of April 6, 2026), Upside Potential 42.0%
  • Valuation Methodology: Coverage initiated with a Target Price of KRW 1,150,000 by applying a Target P/E multiple of 37.4x to the 2028 estimated EPS of KRW 30,128
  • Financial Forecasts & Historicals:
    • 2026E: Revenue KRW 5,049 Billion, Operating Profit KRW 489 Billion, Controlling Net Profit KRW 386 Billion, EPS KRW 17,564, PER 49.0x, PBR 10.8x, EV/EBITDA 22.0x, ROE 24.3%, Dividend Payout Ratio 25.4%
    • 2027E: Revenue KRW 6,021 Billion, Operating Profit KRW 632 Billion, Controlling Net Profit KRW 499 Billion, EPS KRW 22,694, PER 37.9x, PBR 8.8x, EV/EBITDA 17.9x, ROE 25.6%, Dividend Payout Ratio 25.4%
    • 2028E: Revenue KRW 7,223 Billion, Operating Profit KRW 839 Billion, Controlling Net Profit KRW 663 Billion, EPS KRW 30,128, PER 28.5x, PBR 7.0x, EV/EBITDA 14.3x, ROE 27.4%, Dividend Payout Ratio 23.1%
  • Stock Indicators: KOSPI 5,450.33pt, 52-Week High KRW 860,000, 60-Day Avg Daily Trading Value KRW 264 Billion, Outstanding Shares 22.0 Million shares, Market Cap KRW 17,820 Billion, Foreign Ownership 24.28%, Major Shareholders LIG & 8 affiliated parties (38.21%), National Pension Service (9.67%)

2. [Market Opportunities & Business Outlook]

  • 1Q26 Earnings Outlook:
    • Consolidated revenue projected at KRW 1,028 Billion (+21.5% YoY, -21.5% QoQ) and operating profit at KRW 129.5 Billion (+14.0% YoY, +234.8% QoQ), slightly above market consensus (KRW 110.3 Billion).
    • UAE Cheongung-II recognition follows scheduled percentage-of-completion accounting rather than an unexpected one-off surge; long-term focus should remain on multi-year backlog conversion and surging global demand.
  • Sequential Middle East Deliveries & Subsidiary Turnaround:
    • UAE Cheongung-II mass-production deliveries accelerate in 2026, followed by sequential delivery additions from Saudi Arabia in 2027 and Iraq in 2028, driving sustained export mix expansion and top-/bottom-line growth.
    • Ghost Robotics (GRC) is projected to narrow operating losses in 2026 and turn profitable starting in 2027.
  • Global Interceptor Scarcity & System Integration Strength:
    • Limited global interceptor capacity elevates Cheongung-II’s market positioning, driving potential follow-on procurement and early delivery requests from existing clients (UAE, Saudi Arabia, Iraq).
    • Expanding new export contracts expected across the Middle East and Europe, alongside higher potential for early international contract execution for L-SAM.
    • Solidified positioning as a defense Top-Pick due to integrated domain leadership across all three modern warfare pillars: ISR (Intelligence, Surveillance, and Reconnaissance), C4I, and PGM (Precision Guided Munitions).

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not merely through quarterly delivery milestone timings, but as a top-pick defense contractor warranting a sustained valuation re-rating given acute global interceptor shortages and integrated capabilities across modern warfare systems (ISR, C4I, PGM). This perspective prioritizes the sequential top- and bottom-line expansion anchored by Middle Eastern mass-production ramps (UAE in 2026, Saudi Arabia in 2027, Iraq in 2028) and early export prospects for L-SAM over short-term valuation concerns.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the execution of UAE Cheongung-II deliveries, follow-on procurement or early delivery requests from the three Middle Eastern clients, new contract awards in Europe and the Middle East, early export traction for L-SAM, and GRC’s operational turnaround by 2027. These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Readout · ABL111 Phase 3 · Grabody B Expansion / 2026-04-07
Next Post: [Research] SK hynix (000660 / SKHY) – Kiwoom | Server DRAM · eSSD · Earnings Upgrades / 2026-04-09

Related Posts

  • [Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Supply Discipline · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | HBM4 · Product Mix · LTA / 2026-07-30 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | BBU Momentum · Hungarian Utilization Rebound · 2026 Operating Profit Turnaround / 2026-03-18 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | ESS & BBU Momentum · Europe Market Share Recovery · 4Q26 Turnaround / 2026-04-29 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | ADR Listing · HBM Pricing · Valuation Re-rating / 2026-06-30 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] Samsung Electro-Mechanics (009150) – Kyobo Securities | AI Server Demand · High-Value Mix · Structural Profitability / 2026-07-31 Research
  • [Research] Hanwha Ocean (042660) – Hana Securities | Merchant Vessel Margin Expansion · Energy Supply Chain Shift · Order Momentum / 2026-07-28 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Plant 5 Operation · Fixed-Cost Operating Leverage · Plant 6 Expansion / 2026-05-19 Research
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | Sequential Segment Recovery · Order Pipeline Visibility · Form Factor Diversification / 2026-04-29 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | 4Q25 Review · Conservative 2026E Guidance · Long-term Structural Growth / 2026-02-19 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme